Citations

Clear

148 citation(s) found for "Ho, Carole".

The CREB-regulated co-activators 2/3, have a role, in vivo, in osteoblastic gene expression.
Le Henaff, Carole A , Partridge, Nicola C

Mayo Clinic

No container title available | September 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.21.753306 | PMID 42818168 Get It

Many hormones and substances acting through G-protein coupled receptors and protein kinase A (PKA) activation inhibit the salt-inducible kinases (SIKs) by phosphorylation. SIKs tonically phosphorylate CREB-regulated transcriptional coactivators (CRTC1, 2 and 3), sequestering them in the cytoplasm and, thus, preventing their translocation into the nucleus. Once in the nucleus, CRTCs bind CREB family member transcription factors and enhance their activity. We and others have shown that parathyroid hormone (PTH) activation of PKA and resultant SIK2/3 inhibition allows CRTC2/3 nuclear translocation. One of the major actions of CRTC2/3 in the osteoblast lineage is the regulation of transcription of Rankl, as well as other PTH-controlled genes. However, little is known about the role of these co-activators in the osteoblast lineage in vivo. Here, we have investigated whether there are basal effects in vivo on bone examined at 2 different ages of conditional deletion of these two co-activators in the osteoblast lineage using Col2.3-Cre. We found significant increases in body weight, length, bone mineral density, bone volume/total volume, trabecular thickness and number with decreased trabecular separation in young (2 months old) male mice, all of which dissipated by 6 months of age. Female mice showed minimal changes in the bone phenotype at either age. Nevertheless, there were gene expression changes in bones of both sexes at both ages, and in particular decreases in Rankl, Runx2 and Sost, and accompanying changes in Wnt pathway genes. These effects may explain the changes in the bone phenotype in the young male mice, but it is notable that there is a sexual dimorphism in the action of CRTC2 and CRTC3. Overall, the work supports the data from research in vitro and forms a basis for investigation of the role of these co-activators in PTH action in vivo.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Wilson, Matthew R. , Lewis, Katharine L. , Kirkwood, Amy A., Cwynarski, Kate , Cheah, Chan Y. , El-Galaly, Tarec C., Villa, Diego , Savage, Kerry J. , Bobillo, Sabela , Smedby, Karin E. , Puckrin, Robert , Fox, Christopher P. , Bishton, Mark, Thanarajasingam, Gita , Hapgood, Greg , Soussain, Carole , Choquet, Sylvain , Mel, Sanjay De , Preston, Gavin, Hawkes, Eliza A. , Clavert, Aline, Ku, Matthew , Narkhede, Mayur , Durot, Éric , Smith, Jeffrey , Eyre, Toby A. , Ghione, Paola , E Smedby, Karin , Harrysson, Sara , Trnĕný, Marek , Puckrin, Robert , Fox, Christopher P , Thanarajasingam, Gita , Doo, Nicole Wong , Hapgood, Greg , Soussain, Carole , Choquet, Sylvain , Dickinson, Michael , Talaulikar, Dipti , Preston, Gavin , Ahearne, Matthew , Hawkes, Eliza , Schorb, Elisabeth , Clavert, Aline , Ku, Matthew , Narkhede, Mayur S , Calimeri, Teresa , Durot, Eric , Smith, Jeffrey , Renaud, Loïc , McKay, Pamela , Eyre, Toby A , Savage, Kerry J , Cheah, Chan Yoon , Lewis, Katharine L , Kirkwood, Amy, El‐Galaly, Tarec Christoffer , Ghione, Paola , Trněný, Marek , Klánová, Magdalena , Bishton, Mark , Doo, Nicole Wong , Dickinson, Michael , Talaulikar, Dipti , Guidetti, Anna

Mayo Clinic

Journal of Clinical Oncology | June 11, 2026 | Volume: 44 | Issue: 24 | Pages: 2290-2302

10.1200/jco-26-00947 | PMID 42274647 Get It

PURPOSE In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients. METHODS Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the following criteria: CNS international prognostic index score 5-6; testicular, renal/adrenal, or breast involvement; ≥3 extranodal sites), treated with or without HD-MTX. The primary outcome was CNS relapse rate (isolated or concurrent with systemic relapse) measured from diagnosis with additional landmark analysis of all responding patients with no progression event at 6 months. RESULTS Analyses were performed on 1,923 patients meeting UHR criteria. No significant difference in 3-year CNS relapse rate was observed between no HD-MTX (n = 1,051) versus HD-MTX patients (n = 872), including in multivariable analyses adjusting for baseline characteristics (3-year rate, 9.3% v 8.1%; adjusted hazard ratio [HR], 1.13 [95% CI, 0.82 to 1.57]). Analyses restricted to isolated CNS relapse also confirmed no difference (5.9% v 5.7%; adjusted HR, 1.03 [95% CI, 0.69 to 1.53]). In the landmark analysis (no HD-MTX n = 782, HD-MTX n = 773), no difference in 3-year CNS relapse was observed (6.7% v 6.6%, adjusted HR, 0.95 [95% CI, 0.62 to 1.44]). CONCLUSION To our knowledge, this is the largest international comparative data set of patients with LBCL with UHR features showing no significant reduction in CNS relapse with HD-MTX in all UHR or in any individual subgroup. Despite inherent limitations of retrospective analyses, the data strongly support previous studies in suggesting HD-MTX prophylaxis has no meaningful benefit for most patients.
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Janelidze, Shorena, Bali, Divya , Dolado, Anna Orduña , Binette, Alexa Pichet , Rahmouni, Nesrine , Blennow, Kaj, Doré, Vincent , Feizpour, Azadeh , Rowe, Christopher C., Villeneuve, Sylvia , Petersen, Ronald C., Jack, Clifford R. , Groups, ADNI, ALFA, and PREVENT-AD Study, Adegoke, Olusegun, Hussen, Kedir Adem, Aisen, Paul, Ajayi, Adeyinka, Amaza, Hannatu, Apostolova, Liana G. , Ashford, Miriam T. , Ayo, Omobolanle, Bernard, Marie , Bernhardt, Haley, Boatwright, Virginia, Borowski, Bret, Brylska, Magdalena, Buckholtz, Neil, Cabrera, Yuliana, Cairns, Nigel J. , Carrillo, Maria, Choe, Mark, Clanton, Taylor, Conti, Cat, Craft, Hannah, Crawford, Karen , DeCarli, Charles , Benedetto, Joseph Di, Diaz, Adam , Drake, Erin, Faber, Kelley, Felmlee, Joel P. , Fidell, Andrea, Flenniken, Derek , Fockler, Juliet , Forghanian-Arani, Arvin, Frank, R.T., Franklin, Erin , Glittenberg, Matt, Gunter, Jeff, Guzmán, Vanessa , Harvey, Danielle, Hedberg, Caitie, Hergesheimer, Lindsey, Hoang, Isabella, Jackson, Jonathan , Jagust, William, Jahanshad, Neda , Jenkins, Cecily, Jiménez, Gustavo , Jin, Chengshi , Kachaturian, Zaven, Kaddurah-Daouk, Rima, Kantarci, Kejal, Karlawish, Jason , Khachaturian, Zaven S., Knaack, Alexander , Korecka, Magdalena , Kormos, Adrienne, Germano, Kaori Kubo, Kwang, Winnie, Lacy, Kaci, Landau, Susan, Lopresti, Brian J. , Magana, Fabiola, Mahboubi, Payam, Malone, Ian G., Masliah, Eliezer , Masterman, Donna, Matoush, Leonard, Miller, Melanie J. , Molchan, Susan, Montine, Tom, Moore-Weiss, John, Neu, Scott, Nosheny, Rachel L. , Ogwang, Sheila, Okonkwo, Ozioma, Parkins, Shaniya, Perrin, Richard J. , Petersen, Ronald, Pizzola, Jeremy, Potter, Zoë, Potter, William Z., Rafii, Michael, Raman, Rema , Reyes, Calvin, Reyes, Denise , Robison, Justin , Chen, Stephanie Rossi, Ryan, Laurie, Sachdev, Pallavi, Saito, Naomi , Salazar, Jennifer, Thao, Mai Seng, Shaffer, Elizabeth , Shaw, Leslie M. , Silverberg, Nina, Strong, Joe, Talavera, Sandra , Taylor‐Reinwald, Lisa, Thal, Leon J., Thomas, Lisa , Thompson, Paul , Tosun, Duygu , Trojanowki, John Q., Sacrey, Diana Truran, Villemagne, Victor L. , Walter, Sarah , Wan, Yang , Ward, Chad, Webb, Caitlin, Weiner, Michael W. , Weisensel, Trinity, Zimmerman, Caileigh, Poirier, Judes, Breitner, John C.S. , Badawy, Mohamed , Baril, Andrée‐Ann, Aguilar, Ricardo A, Gorriti, Annabella B, Gispert, Lidia C, Martinez, Alba C, Iglesias, Ruth D, Julian, Sherezade F, Serra, P, González‐Escalante, Armand , Penas, Laura H, Rodriguez, Gema H, Ninou, Jordi H, Gamaz, Laura Iglesias, Knezevic, Iva, Alvarez, Paula M, Diaz, Tania M, Palacios, Eva , Ballester, A, Mendez, Sandra P, Freixedes, Laura Ros, Vila, Aleix S, Harster, Lluis S, Prat, Anna S, Jaramillo, Marc V, Jack, Clifford R , Feizpour, Azadeh , Doré, Vincent , Pichet Binette, Alexa , Salvadó, Gemma , Janelidze, Shorena , Therriault, Joseph , Brum, Wagner Scheeren , Stomrud, Erik , Mattsson, Niklas , Palmqvist, Sebastian , Coomans, Emma M. , Teunissen, Charlotte E. , Flier, Wiesje M. van der , Benzinger, Tammie L.S. , Gispert, Juan Domingo , Blennow, Kaj , Alcolea, Daniel , Fortea, Juan , Johnson, Sterling C. , Rosa-Neto, Pedro , Schindler, Suzanne E. , Suárez‐Calvet, Marc , Ossenkoppele, Rik , Hansson, Oskar , Groups, ADNI, ALFA, and PREVENT-AD Study, Aisen, Paul , Barnes, Lisa L. , Beckett, Laurel , Das, Sandhitsu R. , Donohue, Michael , Drake, Erin, Erickson, Claire M. , Fletcher, Evan M. , Arani, Arvin , Foroud, Tatiana , Fox, Nick C. , Frank, Richard, González, Hector, Green, Robert C. , Grill, Joshua D. , Harkins, Kristin , Ho, Carole , Hsiao, John , Jo, Taeho, Kaddurah‐Daouk, Rima , Kantarci, Kejal , Koeppe, Robert A. , Largent, Emily A. , Lee, Edward B. , Lee, Virginia M.‐Y. , Morris, John C. , Nho, Kwangsik T. , Nir, Talia M. , Nudelman, Kelly , Okonkwo, Ozioma, Petersen, Ronald, Rabinovici, Gil D. , Rafii, Michael S. , Reid, Robert, Reyes, Denise, Risacher, Shannon L. , Mindt, Mónica Rivera , Sachdev, Pallavi, Saykin, Andrew J. , Schwarz, Christopher G. , Senjem, Matthew L. , Li, Shen , Smith, Stephanie R. , Snyder, Peter J. , Thomopoulos, Sophia I. , Toga, Arthur W. , Vemuri, Prashanthi , Yushkevich, Paul A. , Badawy, Mohamed, Baillet, Sylvain , Minguillón, Carolina , Brugulat‐Serrat, Anna , Cacciaglia, Raffaele , Campo, Marta del , Pascual, Maria, Rodríguez‐Fernández, Blanca , Vilor‐Tejedor, Natàlia

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1122

10.1001/jamaneurol.2025.3217 | PMID 40952756 Get It

Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures Aβ status, determined by CSF or Aβ PET biomarkers. Results Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and Relevance The findings highlight the potential of plasma p-tau217 as a stand-alone test—or when used in a sequential 2-step approach alongside PET or CSF testing—as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments.
Beyond grief: Quantifying bereavement needs of rural family caregivers
Vanderboom, Catherine E., Holland, Diane E. , Ingram, Cory , Gustavson, Allison M. , Mandrekar, Jay , Dose, Ann Marie , Wild, Ellen, Stiles, Carole, Griffin, Joan M. , Vanderboom, Catherine, Holland, Diane, Griffin, Joan M , Kaufman, Brystana G.

Mayo Clinic

Palliative and Supportive Care | September 5, 2025 | Volume: 23 | Issue: No issue available | Pages: No page available

10.1017/s1478951525100205 | PMID 40910421 Get It

Abstract Objectives Family caregivers (FCGs) may experience numerous psychosocial and practical challenges with interpersonal relationships, mental health, and finances both before and after their care recipient (CR) dies. The specific challenges affecting rural FCGs who often have limited access to palliative care services, transitional care, and other community resources are not well understood. The purpose of this paper is to quantify the challenges rural FCGs experienced immediately before the death of a CR and continuing into the bereavement period. Methods A secondary analysis of data from a randomized controlled trial was conducted. The 8-week intervention included video visits between a palliative care research nurse and FCGs caring for someone with a life-limiting illness. Data were from structured interviews during nurse visits with FCGs in the intervention arm whose CR died during the intervention period. Results Ninety (41.8%) of the 215 FCGs experienced the death of their CR. The majority of FCGs were female (58.9%), White (97.5%), spouses or partners (55.6%) and lived with the CR (66.7%). Most FCGs (84%) continued with intervention visits by the study nurse after the CR’s death. Visits resumed on average 7.2 days post-death. The majority of FCGs experienced challenges with grief/coping skills (56%) and interpersonal relationships/support systems (52%) both pre- and post-death of the CR. FCGs also experienced practical challenges with income/finance, housing, and communication with community resources both pre-and post-death. Significance of results Bereavement support should extend beyond a focus on grief to include practical challenges experienced by FCGs. Because challenges experienced in the bereavement period often begin before a CR’s death, there is benefit in continuity of FCG support provided by a known clinician from pre- to post-death. When given an option, many rural FCGs are open to bereavement support as early as a week after the death of a CR.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder
Paner, Gladell P. , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang, Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Reis, Henning , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

Advances in Anatomic Pathology | August 4, 2025 | Volume: 33 | Issue: 1 | Pages: 1-16

10.1097/pap.0000000000000510 | PMID 40757456 Get It

The Dublin ISUP Consensus Conference covered the proceedings on the best practice recommendations on nonurachal glandular lesions of the urinary bladder, bladder diverticular cancers, and molecular features of bladder and urachal glandular lesions. The conference proceedings on urachal neoplasms (except for their molecular features) are published elsewhere. The rationale for convening this conference was the lack of structured and consented pathologic recommendations in these rare lesions. Consensus by participants was reached on the following statements: (1) intestinal metaplasia with dysplasia is considered to be a precursor to primary bladder adenocarcinoma; (2) dysplasia arising from cystitis glandularis should be reported in terms of focality (focal or nonfocal) and grade (low or high); (3) the term “adenocarcinoma” should only be used for carcinomas showing pure (nonurothelial) morphology and should not be used interchangeably in urothelial carcinoma with “glandular differentiation” because of the pathobiological differences and management implications; (4) the different histologic subtypes of bladder adenocarcinoma should be specified in the report; (5) immunohistochemistry has an ancillary role in the work up of bladder adenocarcinoma versus gastrointestinal or Müllerian-type adenocarcinomas; (6) lymphovascular invasion should be included as a parameter when reporting bladder adenocarcinoma; (7) representative or targeted sampling will be sufficient for bladder diverticulum resection specimens; and (8) molecular analysis in genomic profiling should be performed only in advanced or metastatic bladder and urachal adenocarcinomas for targetable therapy. This report on glandular (nonurachal) lesions of the bladder from the Dublin ISUP consensus conference will serve as a best practice recommendation and as a guide for future research on these relatively rare lesions.
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Raghavan, Sheelakumari, Costoya‐Sánchez, Alejandro , Mainta, Ismini , Rodríguez-Fonseca, Omar Darío, Perissinotti, Andrés , Gu, Yuna , Yun, Jihwan, Peretti, Débora Elisa , Aguiar, Pablo , Bischof, Gérard N. , Seo, Sang Won , Villeneuve, Sylvia , O’Brien, John T. , Jagust, William, Frisoni, Giovanni B. , Soleimani‐Meigooni, David N. , Carrillo, Marı́a C., Joie, Renaud La , Rabinovici, Gil D. , Apostolova, Liana G. , Pontecorvo, Michael J. , Johnson, Keith A. , Weiner, Michael W. , Petersen, Ronald C., Jack, Clifford R. , Schöll, Michael , Labonté, Anne , Faubert, Anne‐Marie, Mathieu, Axel, Madjar, Cécile , Carrier, Charles Edouard, Kazazian, Christina, Lepage, Claude, Maillet, David , Michaud, Diane, Couture, Doris, Dea, Doris, Courcot, Blandine, Debacker, Clément , Fontaine, David, Knopman, David S. , Multhaup, Gerhard, Maltais, Jean‐Robert, Breitner, John C.S. , Poirier, Judes, Cheewakriengkrai, Laksanun, Sager, Mark A., Dauar‐Tedeschi, Marina, Rajah, Natasha, Aisen, Paul, Toussaint, Paule‐Joanne , Pierre, Bellec, Kostopoulos, Penelope, Étienne, Pierre , Tariot, Pierre N. , Orban, Pierre , Hoge, Rick, Thomas, Ronald J. , Gauthier, Serge , Craft, Suzanne , Montine, Thomas J. , Nair, Vasavan, Bohbot, Véronique D. , Venugopalan, Vinod, Ituria‐Medina, Yasser, Khachaturian, Zaven S., Teigner, Eduard, Anthal, Elena, Yu, Elsa, Ferdinand, Fabiola, Pogossova, Galina, Mayrand, Ginette, Duclair, Guerda, Gagné, Guylaine, Newbold‐Fox, Holly, Leppert, Illana, Tremblay‐Mercier, Jennifer , Frenette, Joanne, Frappier, Josée, Kat, Justin, Miron, Justin , Wan, Karen, Mahar, Laura, Carmo, Leopoldina, Théroux, Louise, Dufour, Marianne, Lafaille‐Magnan, Marie‐Élyse, Savard, Mélissa, Tuwaig, Miranda, Petkova, Mirela, Rioux, Pierre, Meyer, P.T., El‐Khoury, Rana, Gordon, Renee, Giles, Renuka, Das, Samir, Wang, Seqian, Tabrizi, Shirin , Mathotaarachchi, Sulantha , Dubuc, Sylvie, Lee, Tanya , Beaudry, Thomas, Gervais, Valérie, Pagé, Véronique, Desautels, René, Benbouhoud, Fatiha, Saint‐Fort, Eunice Farah, Verfaillie, Sander C.J. , Farzin, Sarah , Salaciak, Alyssa , Tullo, Stéphanie , Daoust, Leslie‐Ann, Köbe, Theresa , McSweeney, Melissa, Nilsson, Nathalie , Pishnamazi, Morteza, Bedetti, Christophe , Hudon, Louise, Greco, Claudia, Chapleau, Marianne , St‐Onge, Frédéric , Boutin, Sophie , Geddes, Maiya R. , Ducharme, Simon , Jean, Gabriel, Sylvain, Elisabeth, Élie, Marie‐Josee, Leblond‐Baccichet, Gloria, Soucy, Jean‐Paul , Ozlen, Hazal , Bailly, Julie, Mohammediyan, Béry, Chen, Yalin , Remz, Jordana, Rentz, Dorene M., Amariglio, Rebecca E. , Blacker, Deborah , Chhatwal, Jasmeer P. , Dickerson, Brad C., Donovan, Nancy J. , Farrell, Michelle E. , Gómez, Cristina Lois, Marshall, Gad A. , Oaoo, Kate, Price, Julie, Prokopiou, Prokopis C. , Reynolds, Gretchen , Skylar-Scott, Irina A., Vila‐Castelar, Clara , Yang, Hyun‐Sik , Trojanowki, John Q., Green, Robert C, Perrin, Richard J. , Shaw, Leslie M. , Potter, William Z. , Bernard, Marie , Jackson, Jonathan, Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma, Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Mariam, Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Rafii, Michael, Raman, Rema , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Smith, Stephanie , Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Harvey, Danielle, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Kantarci, Kejal, Thompson, Paul , Jahanshad, Neda , DeCarli, Charles , Knaack, Alexander , Fletcher, Evan, Chen, Stephanie R, Choe, Mark, Crawford, Karen , Yuschkevich, Paul A, Reiman, Eric M. , Mathis, Chet, Landau, Susan , Cairns, Nigel J. , Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michal, Neu, Scott, Nho, Kwangsik, Foroud, Tatiana M., Faber, Kelley , Wilmes, Kristi, Thal, Leon J., Dage, Jeffrey L. , Eloyan, Ani , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel, Legarde, Julien, Murray, Melissa E., Newell, Kathy L. , Taurone, Alexander, Thangarajah, Maryanne, Touroutoglou, Alexandra , Clark, David , Day, Gregory S, Duara, Ranjan , Graff-Radford, Neill R, Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Carrillo, María C. , O'Brien, John Tiernan , Jack, Clifford R , Schöll, Michael , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Rial, Alexis Moscoso , Heeman, Fiona , Raghavan, Sheelakumari , Essen, Martijn van , Camacho, Valle , Silva‐Rodríguez, Jesús , Ribaldi, Federica , Coomans, Emma M. , Brum, Wagner Scheeren , Grothe, Michel J. , Drzezga, Alexander E. , Malpetti, Maura , Rowe, James B. , Giessen, Elsmarieke van de , Ossenkoppele, Rik , Smith, Ruben , Hansson, Oskar , Garibotto, Valentina , Dickerson, Bradford Clark , LaMontagne, Pamela , Sperling, Reisa Anne , Vemuri, Prashanthi , Tam, Angela , Binette, Alexa Pichet , Dansereau, Christian , Picard, Cynthia , Michaud, Diane, Couture, Doris, Cuello, A. Claudio , Barkun, Alan , Evans, Alan Charles , Tardif, Christine Lucas , Knopman, David S. , Near, Jamie , Leoutsakos, Jeannie‐Marie , Brandt, Jason , Pruessner, Jens C. , Morris, John C. , Collins, D. Louis , Chakravarty, M. Mallar , Eisenberg, Mark Jeffrey , Rajah, Maria Natasha , Rosa-Neto, Pedro , Bellec, Pierre , Thomas, Ronald, Fonov, Vladimir , Vallee, Isabelle, Vogel, Jacob W. , Dadar, Mahsa , Appleby, Melissa , Meyer, Pierre‐François, Gonneaud, Julie , Pascoal, Tharick Ali , Vachon‐Presseau, Étienne , Spreng, R. Nathan , Rentz, Dorene M. , Buckley, Rachel F. , Gagliardi, Geoffroy Pierre , Gatchel, Jennifer R. , Guzmán‐Vélez, Edmarie , Jacobs, Heidi I.L. , Jutten, Roos J. , Pardilla‐Delgado, Enmanuelle , Price, Julie C. , Quiroz, Yakeel T. , Schultz, Aaron P. , Schultz, Stephanie A. , Sepulcre, Jorge , Vannini, Patrizia , Toga, Arthur W. , Beckett, Laurel , Saykin, Andrew J. , Potter, William, Barnes, Lisa L. , Gonzalez, Hector, Ho, Carole , Hsiao, John , Jackson, Jonathan , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Jimenez‐Maggiora, Gustavo Adolfo , Donohue, Michael , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Kantarci, Kejal , Senjem, Matthew L. , Reid, Robert I. , Fox, Nick C. , Malone, Ian B. , Thomopoulos, Sophia I. , Nir, Talia M. , Tosun, Duygu , Das, Sandhitsu R. , Koeppe, Robert A. , Chen, Kewei , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Ghetti, Bernardino , Grinberg, Lea T. , Hammers, Dustin B , Kirby, Kala, Kukull, Walter A. , Murray, Melissa E. , Polsinelli, Angelina J. , Atri, Alireza , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Musiek, Erik , Salloway, Steve , Turner, Raymond Scott , Wingo, Thomas S , Wolk, S. J. , Womack, Kyle

Mayo Clinic

JAMA | June 16, 2025 | Volume: 334 | Issue: 3 | Pages: 229

10.1001/jama.2025.7817 | PMID 40522652 Get It

Importance Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD). Objective To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes. Design, Setting, and Participants Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included. Exposures Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration– and European Medicines Agency–approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI). Main Outcomes and Measures Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia). Results Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET–positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET–positive/tau PET–negative (17% [95% CI, 13%-22%]) and Aβ PET–negative/tau PET–negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET–positive/tau PET–positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%). Conclusions and Relevance In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms
Reis, Henning , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang , Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Paner, Gladell P. , Lesions, the ISUP Expert Panel on Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, the ISUP Expert Panel on Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

American Journal of Surgical Pathology | June 5, 2025 | Volume: 49 | Issue: 11 | Pages: e18-e26

10.1097/pas.0000000000002416 | PMID 40471793 Get It

This manuscript summarizes the first part of the proceedings of the 2023 Dublin ISUP Consensus Conference encompassing the best practice recommendations on the pathology of neoplasms of urachal origin. The rationale for convening this consensus conference was the lack of structured and consented histopathologic recommendations in these rare tumors. Consensus among the meeting participants (n=80) was reached on the following statements: (1) combination of gross, histologic, clinical and imaging findings with exclusion of secondary tumor metastasis are to be used in the diagnosis of urachal carcinoma; (2) the 2022 World Health Organization (WHO) separate criteria for the diagnosis of urachal adenocarcinoma and for nonglandular carcinoma should be applied; (3) specific elements are to be evaluated and recorded in the gross examination of resection specimens containing urachal tumors; (4) sampling considerations for resection specimens containing urachal tumors are advised; (5) participants are against using 5% or 10% cutoff for the extent of intraepithelial carcinoma in urachal mucinous cystic tumor of low malignant potential; (6) use of immunohistochemical markers for the differential diagnosis of urachal adenocarcinomas in transurethral resection (TUR) specimen is considered optional; (7) similar tumor classificatory (nosology) rules for carcinomas arising from bladder mucosa (eg, urothelial carcinoma, squamous cell carcinoma, and neuroendocrine carcinoma) should be applied for nonglandular urachal carcinomas; (8) a new staging approach other than the previously proposed systems should be designed for urachal carcinoma; (9) a system modifying the current Tumor-Node-Metastasis (TNM)/American Joint Committee on Cancer (AJCC) staging system for urinary bladder cancer is considered appropriate for a study in urachal carcinoma; and (10) several histologic elements are to be reported when diagnosing urachal carcinoma in TUR and resection specimens. This report from the Dublin ISUP consensus conference will serve as a practice recommendation for pathologists and as a guide for future standardized reporting protocols and research regarding urachal tumors. In addition, an international database for urachal cancers under the guidance of ISUP is being planned to be established to address pertinent issues in the pathology of urachal cancers.
Caregiver Communication and Preparedness During Transitions in Care: Results from a Randomized Controlled Trial
Griffin, Joan M. , Kaufman, Brystana G. , Vanderboom, Catherine E., Mandrekar, Jay , Harmsen, William S. , Gustavson, Allison M. , Ingram, Cory , Wild, Ellen, Dose, Ann Marie , Taylor, Erin E., Stiles, Carole, Holland, Diane E. , Mandrekar, Jay N., Wild, Ellen M, Stiles, Carole J, Griffin, Joan M , Taylor, Erin E.

Mayo Clinic

Journal of Palliative Medicine | May 19, 2025 | Volume: 28 | Issue: 6 | Pages: 757-768

10.1089/jpm.2024.0459 | PMID 40387577 Get It

Background: Patients with severe and life-limiting illnesses transitioning out of the hospital often rely on family caregivers (FCGs) to manage communication with health care teams during hospitalizations and outpatient care. However, FCGs infrequently receive adequate training or support to prepare for these responsibilities. Effective communication between FCGs and health care teams is critical for preparing FCGs and reducing risks for poor outcomes. This study tested an eight-week intervention to improve FCG preparedness and communication practices during transitions out of the hospital. Methods: Conducted from 2018 to 2022, this randomized controlled trial included adult FCGs in rural areas in the United States (Minnesota, Wisconsin, and Iowa). FCGs caring for adults who received inpatient palliative care and were transitioning out of the hospital were eligible. The intervention group received teaching, guidance, and counseling from a palliative care nurse interventionist via video visits before and for eight weeks after discharge. The control group received monthly phone calls but no intervention. Outcomes included changes in FCG-reported preparedness for caregiving and communication with health care teams. Results: Of the 429 consented, 367 (183 intervention and 184 control participants) initiated the intervention; 164 had complete preparedness data, and 161 had complete communication data at baseline and eight weeks. In unadjusted analyses, the intervention group showed statistically significant improvements in preparedness but not communication practices. After adjusting for factors associated with care transitions, the findings persisted. Conclusion: Partnering rural FCGs with palliative care nurses via video can improve caregiver preparedness during care transitions. Improving communication practices may need more targeted strategies.
Isolated neurosarcoidosis presenting as granulomatous hypophysitis complicated by arginine vasopressin deficiency
Ghazi, Victor , Sleem, Bshara , Hasbani, Georges El , Kesrouani, Carole , El Hasbani, Georges, Jawad, Ali S. , Uthman, Imad W.

Mayo Clinic

Clinical and Experimental Rheumatology | May 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/xi4pdx | PMID 40371547 Get It